Treatments may involve the following steps: * Prevention includes the use of antibiotics for infection and parenteral anticoagulation for susceptible patients. * Specific therapy includes the use of intravenous heparin and corticosteroids, and possibly plasma exchanges, intravenous immunoglobulin. * As a disease associated with high morbidity and mortality,<unk>  requires an aggressive multidisciplinary treatment strategy. The following treatments have been used in various combinations: anticoagulation, glucocorticoids, plasma exchange, cyclophosphamide, intravenous immunoglobulins, and anti-platelet agents. * Additional steps may have to be taken to manage circulatory problems, kidney failure, and respiratory distress. * Recent investigational treatment therapies include high doses of Rituxan (Rituximab) and eculizumab, which are both humanized monoclonal antibodies that target B cell malignancies and prevent C5 complement cleavage, respectively.
Catastrophic antiphospholipid syndrome
Antiphospholipid syndrome
Primary fibrinogenolysis
Protein C deficiency
Factor VII deficiency
Antithrombin III deficiency
Warfarin resistance
Giant platelet disorder